Valcon Medical Granted Authorisation by The Danish Medicines Agency to Manufacture Cannabis Intermediate products for Danish Pilot Programme
Valcon Medical has a build a state-of-the-art manufacturing facility and rigorous quality control processes ensure the production of pharmaceutical-grade cannabis intermediate products, meeting the strict regulatory requirements set by The Danish Medicines Agency.
COPENHAGEN, DENMARK, July 01, 2023 - Valcon Medical, a leading pharmaceutical company specialising in developing and producing medical cannabis products, is pleased to announce that it has received authorisation from The Danish Medicines Agency to manufacture cannabis intermediate bulk for the Danish pilot programme. This authorisation marks a significant milestone for Valcon Medical and reinforces its commitment to providing high-quality medical cannabis products to patients in Denmark.
The Danish Medicines Agency, responsible for regulating and supervising the pharmaceutical industry in Denmark, has granted Valcon Medical the necessary authorisation to manufacture cannabis intermediate products. This authorisation allows Valcon Medical to produce cannabis intermediates,which is a crucial component in the production of medical cannabis products.
The Danish pilot programme, initiated by the Danish government, aims to explore the potential benefits and challenges associated with medical cannabis. The programme allows patients with specific medical conditions to access medical cannabis products under the supervision of healthcare professionals. Valcon Medical's authorisation to manufacture cannabis intermediate bulk positions the company as a critical player in the Danish pilot programme, contributing to the availability of safe and effective medical cannabis products for chronic patients globally.
"We are thrilled to have received authorisation from The Danish Medicines Agency to manufacture cannabis intermediate bulk for the Danish pilot programme," said Peter Sigetty, COO at Valcon Medical. "This authorisation is a testament to our dedication to meeting the highest standards of quality and safety in the production of medical cannabis products. We are proud to contribute to the Danish pilot programme and provide patients with access to reliable and effective medical cannabis treatments."
As Valcon Medical begins manufacturing cannabis intermediate bulk for the Danish pilot programme, the company remains committed to collaborating with healthcare professionals, patients, and regulatory authorities to advance the understanding and utilisation of medical cannabis in Denmark and globally. Valcon Medical's participation in the pilot programme aligns with its mission to improve patient’s quality of life through the development and production of innovative medical cannabis treatments.
About Valcon Medical
Valcon Medical is a leading pharmaceutical company that researches, develops, and produces medical cannabis products. With a commitment to quality, safety, and innovation, Valcon Medical aims to improve patients' quality of life by providing reliable and effective medical cannabis treatments. Valcon Medical complies with international pharmaceutical standards and collaborates with healthcare professionals, patients, and regulatory authorities to advance the understanding and utilisation of medical cannabis.
You might also be interested in
Valcon Medical is proud to announce its new partnership agreement with a well reputed Polish manufacturer of medicinal cannabis
Introduction of medicinal cannabis to the Polish market requires a marketing authorisation for a pharmaceutical raw material to prepare prescription drugs in the form of non-fibrous hemp herbs, extracts, and tinctures.
Valcon Medical Granted Authorisation by The Danish Medicines Agency for Manufacturing Cannabis Bulk Extracts under the Pilot Programme
With the authorisation to manufacture cannabis bulk extracts under the pilot programme, the company will leverage its expertise to manufacture high-quality cannabis bulk extracts, ensuring strict adherence to regulations and guidelines.
The European Pharmacopoeia Commission (EPC) has adopted a new European monograph for Cannabis flower
The European Pharmacopoeia Commission has adopted a new European monograph for Cannabis flower at the latest Commission meeting in June 2023. The monograph describes quality requirements for the raw material Cannabis flower.